tiprankstipranks
Wuxi Biologics (Cayman) Inc. (WXIBF)
OTHER OTC:WXIBF

Wuxi Biologics (Cayman) (WXIBF) Stock Price & Analysis

111 Followers

WXIBF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.55 - $6.60
Previous Close$1.63
Volume10.50K
Average Volume (3M)57.60K
Market Cap
$7.20B
Enterprise Value$6.59B
Total Cash (Recent Filing)¥9.86B
Total Debt (Recent Filing)¥4.40B
Price to Earnings (P/E)14.0
Beta0.59
Aug 19, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares OutstandingN/A
10 Day Avg. Volume1,298
30 Day Avg. Volume57,601
Standard Deviation0.17
R-Squared0.01
Alpha-0.00083
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside142.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say
Corporate ActionsWuXi Bio has initiated a share repurchase plan with an aggregate value up to US$600mn, demonstrating management's confidence in the business.
Financial PerformanceRevenue from the European market increased by 101.9% YoY in 2023, contributing 30.2% of WuXi Bio revenue.
Market ExpansionSignificant rebound in China market with Chinese customers accounting for about 25% of total new projects.
Bears Say
Financial PerformanceAdj. net profit dropped due to investments in new facilities and digital infrastructure.
Market DemandNon-COVID revenue in China slightly declined due to biotech funding constraints.
Regulatory RiskThe draft Biosecure Act could lead to a shift of customers away from China-based biotech firms to mitigate future risk.
---

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%10.80%6.98%82.22%
0.00%
Insiders
6.98% Other Institutional Investors
82.22% Public Companies and
Individual Investors

WXIBF FAQ

What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?
Wuxi Biologics (Cayman) Inc. lowest stock price was $1.55 and its highest was $6.60 in the past 12 months.
    What is Wuxi Biologics (Cayman) Inc.’s market cap?
    Currently, no data Available
    When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?
    Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Aug 19, 2024 which is in 104 days.
      How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?
      Wuxi Biologics (Cayman) Inc. released its earnings results on Mar 26, 2024. The company reported $0.036 earnings per share for the quarter, missing the consensus estimate of $0.037 by >-$0.001.
        Is Wuxi Biologics (Cayman) Inc. overvalued?
        According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Wuxi Biologics (Cayman) Inc. pay dividends?
          Wuxi Biologics (Cayman) Inc. does not currently pay dividends.
          What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?
          Wuxi Biologics (Cayman) Inc.’s EPS estimate is $0.06.
            How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?
            Wuxi Biologics (Cayman) Inc. has 4,259,139,600 shares outstanding.
              What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?
              Wuxi Biologics (Cayman) Inc. reported an EPS of $0.036 in its last earnings report, missing expectations of $0.037. Following the earnings report the stock price went down -2.247%.
                Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?
                Among the largest hedge funds holding Wuxi Biologics (Cayman) Inc.’s share is Gilder Gagnon Howe & Co LLC.. It holds Wuxi Biologics (Cayman) Inc.’s shares valued at N/A.
                  ---

                  Wuxi Biologics (Cayman) Stock Smart Score

                  Company Description

                  Wuxi Biologics (Cayman) Inc.

                  Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.
                  ---

                  WXIBF Stock 12 Months Forecast

                  Average Price Target

                  $4.11
                  ▲(142.48% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","1.75":"$1.75","3.5":"$3.5","5.25":"$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.850670435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$6.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$4.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.7876866,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$1.79</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,2.096205418076923,2.492410836153846,2.888616254230769,3.284821672307692,3.681027090384615,4.077232508461538,4.473437926538462,4.869643344615384,5.265848762692308,5.66205418076923,6.058259598846154,6.454465016923077,{"y":6.850670435,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,1.8853846153846154,2.0707692307692307,2.256153846153846,2.4415384615384617,2.626923076923077,2.8123076923076926,2.997692307692308,3.183076923076923,3.3684615384615384,3.5538461538461537,3.739230769230769,3.924615384615385,{"y":4.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,1.706745123076923,1.7134902461538462,1.7202353692307693,1.7269804923076923,1.7337256153846154,1.7404707384615385,1.7472158615384614,1.7539609846153845,1.7607061076923076,1.7674512307692307,1.7741963538461538,1.780941476923077,{"y":1.7876866,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.92,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.44,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.8,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.7,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.76,"date":1692921600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.16,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1701993600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Amgen
                  GlaxoSmithKline
                  Biogen
                  Regeneron

                  Best Analysts Covering WXIBF

                  1 Year
                  Chris LuiJefferies
                  1 Year Success Rate
                  0/4 ratings generated profit
                  0%
                  1 Year Average Return
                  -42.08%
                  reiterated a buy rating last month
                  Copying Chris Lui's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -42.08% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis